Background
Lung cancer, of which roughly 80–85% is non-small cell lung cancer (NSCLC) [
1], is one of the leading causes of cancer mortality worldwide [
2]. Especially, incurable NSCLC patients (stages IIIB and IV) have a very short life expectancy with 1-year survival probabilities ranging between 22 and 47% [
3]. Palliative treatment in this setting aims to preserve or improve quality of life, lengthen life, or decrease disease burden. Palliation can consist of symptom relief (best supportive care), or can target tumor tissue itself with, for instance, systemic chemotherapy (CT), radiotherapy (RT), targeted therapies (e.g., epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKI), or immunotherapies.
Individually tailored palliative cancer treatment is essential to ensure that patients receive the treatment that optimally matches their values and preferences, avoiding under- or overtreatment, and optimally utilizing all available healthcare resources. Decision-making in the palliative phase is complex due to the large heterogeneity in this population with regard to histological tumor type, biomarker profile, treatment response, and the marginal expected treatment benefit and the potentially severe toxicity of systemic therapy. Particularly with the rapid developments and breakthroughs in the fields of genomic technologies and molecular therapies for lung cancer, treatment decisions will become more multi-factorial and personalized, and it will become increasingly important to support thoracic oncologists (TO) in staying up-to-date.
Treatment guidelines are quite extensive and general, and do not allow for individual tailoring of treatment. Decision support systems (DSS), as add-ons to existing guidelines, can assist TO in formulating an evidence-based treatment advice by comparing various treatment options for an individual patient. Such tools ideally weigh the pros (e.g., symptom relief, life lengthening) and cons of treatments (e.g., side effects, loss of quality of life), as well as the cost-effectiveness. DSS can consist of (multiple) prediction models, nomograms, and decision trees, which are often based on patient and tumor characteristics. Multiple DSS have been developed for incurable NSCLC patients [
4], such as the prognostic score developed by Florescu et al. [
5] and the nomograms developed by Hoang et al. [
6]. These tools are developed to decide whether certain treatments bring enough gain in overall or progression-free survival to be worthwhile for patients. Research has shown that oncologists tend to overestimate life expectancy of patients [
7,
8], and that they could benefit from using statistical tools providing survival estimates [
7,
9‐
11].
Although there are a large number of DSS available to aid palliative treatment decisions for incurable NSCLC patients [
4], it remains unknown whether the needs of TO are met by the existing tools. Our aim was to shed light on the unmet needs and preferences of TO for future tools in this rapidly developing field.
Discussion
Online inventory questionnaires were filled out by 58 Dutch TO about their needs and preferences regarding DSS for the treatment of incurable NSCLC patients. The majority of the respondents reported that there is a need for newly developed, up-to-date and validated DSS. Based on the results of the current inventory, recommendations can be made for future DSS development. For optimal use in clinical practice, such tools should integrate all relevant treatment options, weigh the benefits and harms of treatments, facilitate communication between caregivers and with patients, and be kept up-to-date.
To support TO’s decision-making, DSS are a useful and time-efficient complement to clinical guidelines for treatment decision-making. Guidelines could even incorporate DSS that are ready for use in clinical practice. Currently, a large number of DSS have been developed for this population, as shown in our previously published systematic review [
4]. Even though the TO in our sample used some of these existing DSS, they reported a need for new tools in their daily practice for multiple goals. Firstly, they missed DSS that show for each individual patient which (combination of) treatments are appropriate, and what the estimated survival gain and toxicities are for each treatment option. Secondly, data on available treatment options, and knowledge from clinical trials, real-life data, and guidelines should be integrated into a DSS. Thirdly, the communication among the different caregivers and with patients could be improved. Lastly, IT solutions were deemed essential, as the challenge will be to design methods for continuous updating of DSS. Moreover, creating clear interfaces for future DSS would make them more suitable to assist in shared decision-making.
Various separate factors, such as performance status, ability to cope, preferences, and the impact on quality of life were reported to be important in clinical decision-making. These are often already incorporated in DSS, but are measured relatively subjectively. Future DSS will need more objective markers, such as genetic and serum markers, in order to reduce unwanted treatment variety and correct use of expensive medication. In the past decades, great progress has been made in the understanding of underlying biological processes of cancer cells. This has led to the discovery of several onco-pathways, which are controlled by oncogenes and tumor suppressor genes. Biological markers are becoming highly influential prognostic and predictive factors for clinical decision-making, as they determine the effectiveness of targeted and immune therapies. In adenocarcinoma and squamous cell carcinoma, various important onco-pathways (e.g., mitogen-activated protein kinase and phosphoinositide 3-kinase pathways) [
12,
13], oncogenes (e.g.,
KRAS,
EGFR,
BRAF), tumor suppressor genes (e.g.,
TP53,
STK11,
CDKN2A), and gene rearrangements (e.g.,
ALK,
ROS, and
RET) have been found to be important [
14‐
16]. Furthermore, angiogenesis and the vascular endothelial growth factor affect the processes of primary tumor growth, proliferation, and metastasis [
17]. In addition, the immune checkpoints programmed cell death protein-1 and programmed cell death ligand-1 pathways have recently emerged as important targets for immunotherapy [
18,
19]. Currently, existing DSS are not up-to-date with regard to such biological markers. Therefore, future tools should incorporate genetic tumor profiles and serum markers to get optimal selection of patients for the myriad of treatment options available. Currently, various national and international guidelines mainly include information about certain genetic mutations of, for example,
EGFR and
KRAS, or rearrangements of, for example,
ALK and
ROS1 [
20‐
23], but there is not a clear decision tool that is tailored to individual patients.
To overcome the reported limitations and to create an adequate tool for future clinical practice, various steps have to be undertaken. It is obvious that oncologist cannot keep up with the current literature to choose the optimal evidence-based treatments, based on a balance between survival gain, side effects, quality of life, patient preferences, and even cost-effectiveness. In addition, the wide array of factors that influence clinical decision-making renders it too complex for the human cognitive capacity. In general, guidelines based on systematic reviews that summarize the evidence of pros and cons of the various treatment options are very useful. Regular updates of the existing guidelines are necessary, but apart from these, DSS can give guidance to decide on the optimal treatment of individual patients. Using the infrastructure of electronic health records for clinical DSS could support personalized medicine practices by providing the tailored information at the right time. Various researchers have discussed the advantages of incorporating DSS in electronic health records in combination with smart algorithms, such that continuous updating and rapid adaptation of DSS are ensured [
11,
24‐
27]. This precision oncology should be a multidisciplinary effort incorporating information from various experts and stakeholders [
24,
25].
There are some ethical issues that were raised in conversations with TO, which should be kept in mind as well. A DSS can support the oncologist in giving treatment advice based on the best available evidence. If the DSS is available online and easy to understand, the given information about pros and cons of treatments can be visualized for patients. Nevertheless, this decision-making process should not be automated, even when good DSS become available; oncologists remain essential in the decision-making process. Furthermore, although the oncologist is offering the best treatment options based on available evidence and clinical knowledge, ultimately, the patient decides. However, patients might not feel capable of choosing between the available treatment options.
The strengths of this study were the fact that we had access to the entire Section of Oncology (SON) of the group of Physicians in Chest Medicine and Tuberculosis organization (largest TO organization in the Netherlands), and these TO were distributed over various hospital settings. Considering the fact that the vast majority of our sample used existing DSS, and reported a need for new tools, it is likely that TO with unmet needs have been more inclined to participate than the oncologists who have less knowledge about or need for DSS. Nevertheless, the current group of responders provided valuable insight in TO’s needs and preferences for new DSS.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.